Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...